Hospice brings substantial clinical benefits to dying patients and families but is underutilized by patients dying of hematologic malignancies (HM); nationwide, only 2% of HM patients use hospice. There are 70,000 deaths among U.S. patients with hematologic malignancies yearly.
Objective:
We measured the use and length of stay (LOS) in hospice among patients with HMs at a large academic cancer center.
Design:
This was a single center retrospective review of adult patients (≥18 years) with lymphoma, leukemia, myelodysplastic syndrome, aplastic anemia, and multiple myeloma referred for hospice.
Measurements:
Information included demographics, transplant, hospice type, LOS, and use of “expanded access” services.
Results:
Fifty-nine patients were referred to hospice, and 53 utilized hospice services, 25% of 209 HM decedents. Thirty-five received home hospice and 18 used inpatient hospice. The median home hospice LOS was nine days (SD 13) and inpatient hospice six days (SD 10). Nine patients with “expanded access” hospice received only a few blood transfusions, and none received radiation.
Conclusions:
HM patients are referred late or never for hospice services. Studies evaluating earlier integration of palliative and hospice care with usual HM care are warranted. We present a one-page negotiation form that we have found useful in negotiations among HM physicians, hospice medical directors, and payers.
Get full access to this article
View all access options for this article.
References
1.
SmithTJ, TeminS, AlesiE, et al.: American Society of Clinical Oncology provisional clinical opinion: The integration of palliative care into standard oncology care. J Clinical Oncol, 2012; 30:880–887.
2.
SmithTJ, SchnipperLJ: The American Society of Clinical Oncology Program to Improve End-of-Life Care. J Palliat Med, 1998; 1:221.
3.
PeppercornJM, SmithTJ, HelftPR, et al.: American Society of Clinical Oncology statement: Toward individualized care for patients with advanced cancer. J Clin Oncol, 2011; 29:755–760.
4.
NelsonC, ChandP, SorataisJ, OloimoojaJ, RembertG: Inpatient palliative care consults and the probability of hospital readmission. Perm J, 2011; 15:48–51.
FitchK, PyensonP: Cancer patients receiving chemotherapy: Opportunities for better management. New York: Milliman, 2010.
7.
ManittaVJ, PhilipJAM, Cole-SinclairMF: Palliative care and the hemato-oncological patient: Can we live together? S review of the literature. J Palliat Med, 2010; 13:1021–1025.
8.
ChowK, CoyleN: Providing palliative care to family caregivers throughout the bone marrow transplantation trajectory: Research and practice: Partners in care. J Hosp Pall Nursing, 2011; 13:7–13.
9.
EpsteinAS, GoldbergGR, MeierDE: Palliative care and hematologic oncology: The promise of collaboration. Blood Rev, 2012; 26:233–239.
10.
GrundyM, GhaziF: Research priorities in haemato-oncology nursing: Results of a literature review and a Delphi study. Eur J Oncol Nurs, 2009; 13:235–249.
11.
LeeSJ, FaircloughD: Discrepancies between patient and physician estimates for the success of stem cell transplantation. JAMA, 2001; 285:1034–1038.
12.
ChantalJNM, NeilMJB, SamA: What investigations and procedures do patients in hospices want? Interview based survey of patients and their nurses. BMJ, 1997; 315:1202–1203.
13.
MercadanteS, FerreraP, VillariP, DavidF, GiarratanoA, RiinaS: Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. J Palliat Med, 2009; 12:60–63.
14.
American Cancer Society: ACS Facts and Figures. American Cancer Society, 2010.
15.
MaX, DoesM, RazaA, MainST: Melodysplastic syndromes: Incidence and survival in the United States. Cancer, 2007; 109:1536–1542.
16.
EarleCC, ChapmanRH, BakerCS, et al.: Systematic overview of cost-utility assessments in oncology. J Clin Oncol, 2000; 18:3302–3317.
17.
SmithTJ, HillnerBE: Bending the cost curve in cancer care. N Engl J Med, 2011; 364:2060–2065.
18.
RileyGF, LubitzJD: Long-term trends in Medicare payments in the last year of life. Health Serv Res, 2010; 45:565–576.
19.
GaetaS, PriceKH: End-of-life issues in critically ill cancer patients. Crit Care Clin, 2010; 26:219–227.
20.
KelleyAS, DebP, DuQ, Aldridge CarlsonMD, MorrisonRS: Hospice enrollment saves money for Medicare and improves care quality across a number of different lengths-of-stay. Health Aff, 2013; 32:552–561.
21.
ChristakisNA, IwashynaTJ: The health impact of health care on families: A matched cohort study of hospice use by decedents and mortality outcomes in surviving, widowed spouses. Soc Sci Med, 2003; 57:465–475.
22.
MordenNE, ChangCH, JacobsonJO, et al.: End-of-life care for Medicare beneficiaries with cancer is highly intensive overall and varies widely. Health Aff, 2012; 31:786–796.
23.
National Hospice and Palliative Care Organization: NCHPO Facts and Figures: Hospice Care in America. National Hospice and Palliative Care Organization, 2012.
TenoJM, CasarettD, SpenceC, ConnorS: It is “too late” or is it? bereaved family member perceptions of hospice referral when their family member was on hospice for seven days or less. J Pain Symptom Manage, 2012; 43:732–738.
26.
FurmanCD, DoukasDJ, ReichelW: Unlocking the closed door: Arguments for open access hospice. Am J Hosp Palliat Care, 2010; 27:86–90.
27.
FreundK, WeckmannMT, CasarettDJ, SwansonK, BrooksMK, BroderickA: Hospice eligibility in patients who died in a tertiary care center. J Hosp Med, 2012; 7:218–223.
28.
WeckmannMT, FreundK, BayC, BroderickA: Medical manuscripts impact of hospice enrollment on cost and length of stay of a terminal admission. Am J Hosp Palliat Care, 2012; 1–3.
29.
Wittenberg-LylesE, DillerA, Sanchez-ReillyS, RegehrK: Does exposure to palliative care prior to hospice make a difference for caregivers?. J Palliat Med, 2009; 12:6.
30.
MorrisonRS, DietrichJ, LadwigS, et al.: Palliative care consultation teams cut hospital costs for Medicaid beneficiaries. Health Aff, 2011; 30:454–463.
31.
MeyerH: Changing the conversation in California about care near the end of life. Health Aff, 2011; 30:390–393.
32.
HowellDA, ShellensR, RomanE, GarryAC, PatmoreR, HowardMR: Haematological malignancy: Are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. Palliat Med, 2011; 25:630–641.
33.
LangK, EarleCC, FosterT, DixonD, Van GoolR, MenzinJ: Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging, 2005; 22:943–955.
34.
IwashynaTJ, ZhangJX, ChristakisNA: Disease-specific patterns of hospice and related healthcare use in an incidence cohort of seriously ill elderly patients. J Palliat Med, 2002; 5:531–538.
35.
FadulN, ElsayemA, PalmerJL, TaoZ, BraitehF, BrueraE: Predictors of access to palliative care services among patients who died at a comprehensive cancer center. J Palliat Med, 2007; 10:1146–1152.
36.
SalpeterSR, MalterDS, LuoEJ, LinAY, StuartB: Systematic review of cancer presentations with a median survival of six months or less. J Palliat Med, 2012; 15:175–185.
37.
KumarSK, LeeJH, LahuertaJJ, et al.: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012; 26:149–157.
38.
WitzigTE, TangH, MicallefIN, AnsellSM, et al.: Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood, 2011; 118:4882–4889.
39.
KadiaTM, JabborE, KantarjianH: Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol, 2011; 38:682–692.
40.
Al-aliHK, JaekelN, JunghanssC, et al.: Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: A multicenter phase I/II study. Leuk Lymphoma, 2012; 53:110–117.
41.
GargRJ, KantarjianH, O'BrienS, Quintás-CardamaA, FaderlS, EstrovZ, CortesJ: The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up. Blood, 2009; 114:4361–4368.
42.
CortesJ, LiptonJH, ReaD, et al.: Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood, 2012; 120:2573–2580.
43.
WierdaWG, KippsTJ, StilgenbauerS, et al.: Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol, 2010; 28:1749–1755.
